Recombinant immunotoxins

descriptionPublicationkeyboard_double_arrow_right Article 01 Feb 1996 English Publisher:Springer Science and Business Media LLCJournal:Breast Cancer Research and Treatment, volume 38, pages 3-9 (issn: 0167-6806, eissn: 1573-7217,

Copyright policy )

Authors: I, Pastan; L H, Pai; U, Brinkmann; D, FitzGerald;

doi: 10.1007/bf01803778

pmid: 8825117

Recombinant immunotoxins

- Summary
- Subjects
- Metrics

Abstract

Pseudomonas exotoxin has been genetically modified so that it targets cancer cells. This was accomplished by deleting its cell binding domain and replacing it with Fv fragments of antibodies that react with breast, colon, and other cancers. Several recombinant immunotoxins are now in clinical trials.

Related Organizations

National Institutes of Health
United States
National Cancer Institute
United States

Keywords

ADP Ribose Transferases, Virulence Factors, Immunotoxins, Bacterial Toxins, Antibodies, Monoclonal, Exotoxins, Breast Neoplasms, Recombinant Proteins, Humans, Female, Pseudomonas aeruginosa Exotoxin A

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	22
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 10%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 10%